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Prostate cancer is the second leading cause of cancer related diseases among men. Prostate cancer initially responds good to androgen ablation therapy. In the beginning of the disease the prostate is still hormone sensitive, but later patients will evolve a lethal castration refractory form of the disease. Canine prostate cancer mostly resembles human androgen refractory  poorly differentiated  prostate cancer. It originates from the collecting ducts probably. [15,30] There already has been developed a marker protein for human prostate cancer known as Prostate specific antigen (PSA), which is used to detect prostate carcinoma in men. However the significant false positive rate is very high, which results in taking unnecessary painful biopsies from the prostate. That’s why we are trying to find a new marker protein with a higher sensitivity and which still has got the required specificity, which can be used for prostate cancer screening and diagnosis.[22,32]         
 Research done  in the United States has revealed six protein peaks which can be possible plasma protein markers in dogs which developed canine prostate tumor. These proteins are: beta defensine 138, a fragment of KCNE2, a fragment of masticator myosin heavy chain 16, a fragment arginine_vasopressine precursor, nonhistone chromosal protein HMG-17 and apolipoprotein cI precursor (apo-cI). These proteins are created by a process of transcription and translation of the genes in canine prostate carcinomas. Earlier research has been done to genes coding for the six proteins which come to an over expression in the biopsies of the prostate tumors. The over expression of these proteins in prostate carcinoma cell lines (CPA and ACE) are in this research compared to a normal prostate cell line (CAPE) and a transitional cell line (k9TCC) in the dog. The goal of this research is to find out if the genes of the six proteins come to over expression in the two cell cultures of canine prostate carcinomas, in comparison to a normal prostate epithelium cell line and a transitional cell carcinoma cell line. If the six proteins come to a over expression, it would be possible to reveal prostate tumours with blood examination. The research also indicated that the protein plasminogen (plasmin precursor) was a possible marker protein.[22]                          
Canine prostate tumors
The mean age to develop prostate tumors in the dog is about 10 years. These tumors are invasive and will have metastases to the sublumbar lymph nodes, the Pelvic area and the lumbar vertebrae. Clinical symptoms like tenesmus, dyschesie, strangurie, locomotion problems and weight loss are often visible. Palpation is painful, the gland isn’t strongly extended, and the contour can be irregularly.  The consistency is harder then normal. Usually the prostate goes in regression after castration, so you have to think of an prostate carcinoma when you see a castrated dog with a normal to an enlarged prostate. The diagnosis is suspected by abdominal and rectal palpation and echo. The diagnosis is acknowledged by accomplishing a fine needle aspiration biopsy. Treatments like surgery, chemotherapy, hormone therapy and radiation haven’t lengthened the dog’s life yet, nor improved the quality of life. Other diseases that can be diagnosed with these symptoms are: benign prostate hyperplasia, metaplasia of the prostate epithelium by estrogen influences, bacterial prostatitis, prostatic abscesses and paraprostatic cysts. Contrary, these diseases can be treated by castration, stopping estrogen therapy, by antibiotics or cyst dissection. [20,22]                                                                     
Comparison of the canine prostate with the human prostate. 
The normal human prostate is divided in three zones: the peripheral zone, the transitional zone and the central zone. Glands of the peripheral zone have a rounded shape. About 70-75% of the carcinomas arise in this zone. In the transitional zone arise 15-20% of the carcinomas arise, while it is the main source of benign prostate hyperplasia (BPH). Glands from the central zone are larger and appear often in lobules. The epithelium of this zone has got a granular cytoplasm and only 10% of the carcinomas arise from it.                                                           The canine prostate lacks the human zonal differentiation. There isn’t a preferential site for rising of BPH either. The acinic structures in the dog are much more prominent then in human prostates.[15]                                                                                                                                             Human prostate epithelium of two cell layers: a basal cell layer, which exists of flat to triangular cells and a luminal layer, which are cubical to columnar. The basal cell layer is considered to be the precursor of the luminal cell layer.                                                                  In the canine prostate two intermediate cell layers have been identified. The canine prostate epithelium is more differentiated, has got more acini and less stromal tissue. At castration the epithelium goes into regression and changes from an acinair to a tubular aspect, with a single lining of epithelial cells.                                                  
Comparison of human prostate carcinoma with canine prostate carcinoma
As in human prostate carcinoma, canine prostate carcinoma appear spontaneously in elderly dogs. In addition, the tumor grows beyond the borders of the prostate and  metastases appear in longs and bones usually. [15]                                                                                                 Prostate tumors are classified by the World Health organization (WHO) in adenocarcinomas and less differentiated tumors. Adenocarcinomas are further divided in intra alveolar, which is the most common one and acinar.                                                                                          High grade prostatic intraepithelial neoplasia (PIN lesions) are considered as the precursor of human prostate cancer. Also in canine prostate cancer, these lesions appear more often.                In humans, 95% of the prostate carcinomas are adenocarcinomas, often characterized by acinar differentiation. The remaining 5% are poorly differentiated carcinoma’s, in which the tumor cells aren’t lined by acini. In androgen sensitive prostate carcinoma  have glandular, micro-glandular and cribiform growth patterns The hormone refractory are classified as fused glands, medullary/ solid en columnar /trabecular patterns. Metastases appear to have androgen refractory growth patterns. [4,16]                                                                                                                                   
Canine prostate tumors develop from ductal epithelium. At castration, there is an increased risk of developing prostate carcinomas. A less differentiated prostate epithelium develops at castration, in which secretory epithelium regresses and the ductal epithelium remains. The tumor contains more stem cells and transiently amplifying cells.[16]       
 In the dog a different classification systems have been used. This is one of the classification systems:

	 Most observed: Cribiform, Solid, micropappilary
Solid, infiltrating growth patterns were significantly more observed in castrated dogs than in non-castrated dogs. Castrated dogs had less differentiated and more solid growth patterns and adenocarcinoma have been less observed.                                                                                  A different classification system used in canine prostate cancer described intra alveolar, small acinar, syncitial, discrete alveolar and poorly differentiated growth patterns. The small acinar growth pattern was the most common subtype in the normal dog and intra alveolar in the castrated dog. In the various classification systems, the primary tumor had a mixed morphology and had two or more growth patterns.                                                                        The canine prostate tumor seems to be more aggressive and of a less differentiated growth type than human androgen sensitive prostate carcinoma. Less differentiated means  histomorphological a solid infiltrating growth patter versus adenocarcinoma in humans. In addition, a less differentiated cellular growth pattern was observed. Canine prostate carcinomas are also androgen unresponsive. So canine prostate cancer mostly resembles human, androgen refractory, poorly differentiated prostate cancer.[15]
PSA and PSMA
 Prostate specific membrane antigen (PSMA) is a human prostate carcinoma marker protein. This protein was clearly expressed by RT-PCR in the canine prostate and its expression was enhanced by a factor 5 in prostate carcinomas of the dog. In addition, PSMA expression was found in canine prostate cell lines. In a comparative study of   PSMA expression was stated that dogs do not express PSMA at all, but that can be the result of the use of a primer with a very low predicted melting temperature.  In addition, in this research only tissues have been used of the normal prostate, which had an expression which was five fold lower than prostate carcinoma. I couldn’t find in literature if PSMA could be detected in canine blood. If it can be detected in blood, it could be possible that it could serve as a possible marker protein for canine prostate cancer. Prostate specific antigen (PSA) is another human marker protein, which is  used for detection of prostate cancer. PSA had a low expression for canine prostate cancer. [2,15,27]      
The androgen receptor and the Wnt /β-catenine signal path
Prostate cancer is the number two cause of death of cancer. A great number of the patients develop a hormone insensitive tumor from a carcinoma that still reacts to androgen therapy. The hormone insensitive stadium can have different causes. The tumor has increased levels of the androgen receptor. [4] In addition, the mRNA and the protein levels of the androgen receptor (AR) increase.                                                                                                             Androgen receptor activating mutations and coactivator up regulation are possibly involved in developing the hormone insensitive state. The Wnt family has an important role in stem cell or progenitor cells renewal and maintenance. When this pathway deregulated, several tumors can arise. In the normal prostate, β-catenine accomplishes that precursor cells are renewed in the basal part of the acini of the prostate.                                                                                        The Wnt/β-catenine pathway can  stimulate the transcription activity of the AR, so the sensitization of the AR enhances, which gives an advantage in growth of the tumor cells. The other way round, stimulates the AR over expression the Wnt/β-catenine transcription activities.  β-catenine contributes to the prostate cancer development by stimulating the AR transcription activity in the presence of androgens. At castration  level, the AR has an  interaction to the Wnt signal and enhances the prostate cancer cell development proliferation.. Androgen receptor agonists inhibit the AR stimulation of the Wnt/β-catenine pathway. The re-establishment to physiological levels of androgens can  reduce the malignity and the refractarity of the prostate cells. This could be done by inhibiting the AR in the  Wnt/β-catenine pathway. Physiological levels of androgens inhibit growth and transformation of tumor cells mediated by the Wnt signal and the AR over expression.
Normal prostate cells                                                                                                                    - Wnt/β-catenine pathway and androgen  receptor pathway function in different cell populations                                                                                                                                   Hormone sensitive prostate carcinoma cells                                                                                  -In prostate cancer cells in which both the Wnt/β-catenine pathway and  the androgen  receptor appear in the same cell population  and in which they are both deregulated , androgens still inhibit the Wnt/β-catenine pathway, while β-catenine stimulates the transcription activity of the androgen receptor.                                                                           Hormone insensitive prostate carcinoma cells                                                                               -High levels of Wnt -1 and β-catenine, correspond  to the appearance of metastatic hormone insensitive prostate carcinomas.                                                                                                   -There are enhanced levels of androgen receptors and  because of  this, the transcription activities of  the Wnt/β-catenine pathway are stimulated.                                                                       -The androgen receptor signals through the Wnt/β-catenine pathway, so that tumor cells become malignant  in a ligand independent way.                                                                                                                                                           –The simultaneous  activation of the Wnt/β-catenine pathway and the enhanced levels of androgen receptors, while androgens are at castration level, stimulates prostate cell growth and transformation.                                                                                                                                 –The re-establishment to physiological androgen levels, inhibits  further tumor cell growth and transformation, which was caused by the simultaneous activation of the enhanced AR concentration and  the Wnt /β-catenine pathway. So the malignity could be inhibited by the re-establishment to physiological levels of androgens, possibly by inhibiting the influence of the AR in the Wnt /β-catenine pathway (see figure 2). [4,30]

Figure 2: Interaction of the androgen receptor (AR) and the Wnt-β-catenine pathway. A and B: In normal conditions the Wnt-β-catenine pathway and the AR pathway function in different cell lines. C: In androgen sensitive prostate cancer cells, androgens may inhibit the input of the androgen receptor into the Wnt-β-catenine pathway, while β-catenine stimulates the AR. D: In androgen refractory prostate cancer cells, the Wnt signal activates both the AR and the Wnt-β-catenine pathway. The AR signals trough the Wnt β-catenine pathway to promote tumor cell malignancy. [30]




The discovery of the protein peaks
It’s important that there is a reliable biomarker of prostate cancer which can be used for large groups and diverse patients without the loss of predictable values. In a research performed in the united states by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF mass spectrometer), six protein peaks at 2086, 7050,7633, 7875,9330,13785 have been detected. These protein peaks have been identified using the NCBI’s protein data base. The following protein peaks have been discovered: a fragment of kcne2 (gastric cancer), masticatory myosin heavy chain (MYH16), arginine-vasopressine precursor (AVP2) (probably involved in long cancer), nonhistone chromosomal protein hmg-17 (HMG17) ( probably involved in the transition of prostate carcinoma becoming unresponsive to androgen ablation therapy) apolipoprotein cI precursor (apo-cI) en Beta defensine 138 (BD138) (see table 1). Eventually all these proteins have been investigated in expression level by qPCR.[22]
In this research, all these proteins turned out to come to a higher expression except beta defensine 138 and arginine_vasopressine precursor. In addition there turned out to be an other protein peak at  13785 Da. Three proteins could possibly have the same molecular weight based on a PowerPoint presentation of the manuscript of the research from the united states.[22] These proteins were the plasmin precursor, histone H2a and ribosomal fragment protein. In the following research, only the expression of the plasmin precursor of the 13785 peak, was investigated, because histine H2a and the ribosomal fragment weren’t named in the manuscript anymore(while they were named in the power point presentation of the manuscript). In addition there also was a protein peak at 2084 Da, which couldn’t be identified (see table2).
Table 1 :protein peaks in plasma of dogs with prostate carcinoma identified according to the protein database[22]
	Protein peak in Da	Expected protein
upregulated	2086	Not identified
down regulated	7050	Kcne2 (fragment)	
up regulated	7633	-Myh16                                                                             -beta defensine
upregulated	7875	AVP
upregulated	9330	-HMG-17                                                                                    -Apo-ci 
down regulated	13785	-Plasmin precursor                                                                        -Similar to A2A histone family, member J isoform 2                - ribosomal protein (fragment) 

De cell lines
In the following research, the emphasis is on the investigation of four cell lines. There are two cell cultures of adenocarcinomas of the canine prostate compared to one cell line of normal prostate epithelium and one cell line of a transitional cell carcinoma. The canine transitional cell line (K9TCC) is epithelium harvested  from cells at the transition of bladder to urethral epithelium. Sometimes, this tumor invades the prostate, which makes it hard to distinguish it from prostate carcinomas.[12,17]                                                                         The two canine prostate tumor cell lines; CPA (canine prostatic adenocarcinoma cell line) and ACE (a spontaneously immortalized canine prostate cancer cell line from a prostate adenocarcinoma), are harvested from canine adenocarcinomas from the prostate.[8,15,30]     In addition a non-neoplastic epithelium cell line (CAPE) from a canine prostate was used.
The potential marker proteins
HMG17
HMG-17 is one of the possible marker proteins which is investigated in this research. HMG-17 (currently also known as HMGN2) is part of the HMGN family. These proteins come to expression in the nucleus and the cytoplasm and they regulate chromatin structure, histone modifications and the rate of transcription. HMG-17 comes to expression during the early embryogenesis of the mouse and occurs less in mature tissues. In absence of transcription, HMG-17 is released and accumulates in interchromatin clusters. In some actively differentiated cells or in renal cells, undergoing a transition of mesenchym to epithelium, HMG-17 is still present.[4,19]






Figure 3: Interaction of the Wnt-β-catenine pathway and HMG-17. When the Wnt signal is off, β-catenine is degraded in the cytoplasm of the cell. Hmg-17 binds to PITX2 and prevents binding of PITX2 to the DNA and prevents transcription. When the Wnt signal is on, β-catenine is transported through the cell membrane and binds to the Hmg-17 PITX2 complex. This complex stimulates transcription. Without Wnt signaling, β-catenine is degraded and transcription no longer takes place.[4]
D-PCA-2                                                                                                                                          In the normal prostate and in prostate carcinomas the gene D-PCA-2 (Dresden prostate carcinoom) will be over expressed. A big part of exon 8 of this gene has a lot of similarity with HMG-17 (93% is homologue). D-PCA-2 isn’t higher expressed in the prostate carcinoma tissue than in normal prostate tissue. On the other hand, D-PCA-2 was found in lymph noduli which contained metastatic cells and wasn’t found in clear noduli.[33]
 APO-C1                                                                                                                       Apolipoproteine c-i precursor (apo-ci) is a big part of very low density lipoprotein (VLDL), a small part of high density lipoprotein (HDL) and a part of human chylomicrons. It binds to phospholipids and stimulated the degradation of cholesterol to cholesterol esters by activation of LCAT. It is highly expressed in the liver.[25,11,14] A research to human Apolipoproteine A-II revealed that this protein was a promising marker protein for prostate carcinoma in men. This research was important because all of the false positives using PSA. This causes men to undergo painful biopsies to exclude prostate tumors.[33] A research about Apolipprotein D revealed that this could be a possible marker protein for malignant transformation of the prostate. In immunohistochemistry the low grade PIN areas were clearly less stained than the high grade pin lesions areas, which are known as the precursor stage of prostate adenocarcinomas. In addition, there was a increasing concentration of APO-D of LG-PIN areas to HG-PIN areas.[5,7,11]
                                                                                                                     
Beta defensine/ AVP2
In the previous research about the expression of the protein peaks, it was decided to stop continuing the research on these proteins, because odds where very low that these proteins could be a marker protein for prostate carcinoma.. The proteins didn’t come to expression in last research. In this research, AVP2 had the hypothalamus as a positive control, because it had the highest expression. The positive control for BD138 was the testis, of which the epididimis gave the highest expression. 
Plasminogen                        
There turned out to be an other protein peak at  13785 Da in the American manuscript about the protein peaks. Three proteins could possibly have the same molecular weight based on a power point presentation of the manuscript.[22] These proteins were the plasmin precursor, histone H2a and ribosomal fragment protein. In the following research, only the expression of the plasmin precursor of the 13785 peak, was investigated, because histone H2a and the ribosomal fragment weren’t named in the manuscript anymore (while they were named in the power point presentation of the manuscript).                                                                               In this research plasminogen seemed to be down regulated, but in an other article it was thought to be up regulated in prostate carcinoma[3,22]. In this second article it was thought to be expressed in the prostate  and over expressed in a later stage of the disease. This is why it was interesting to do more research to plasminogen expression in the canine prostate carcinoma. This way, it can be investigated if the expression of plasminogen is enhanced in cell lines of prostate tumors of the dog  (ACE and CPA), compared to a transitional cell line (K9TCC)and an epithelial cell line of a canine prostate, absent of tumor cells (CAPE).                                      In addition we want to investigate if plasminogen was increased in expression in collected tissues of prostate carcinomas (PCAi) in comparison to mammary tumors, fibroblastic tissue, masseter tissue, heart tissue and liver tissue.[2] Furthermore is plasminogen an interesting protein to investigate, because it probably has a part in arising of a prostate tumor in general.[10,27,33]                                                                                                                           The proenzyme plasminogen is first converted to the serine proteinase plasmin, by urikinase type plasminogen activator (uPA) which in turn promotes angiogenesis and tumor cell invasion by activating  matrix metalloproteinase’s [6,22]. Expression of (uPA) by malignant cells correlates with an aggressive phenotype, including increased invasiveness, tumor-associated angiogenesis, and metastases. The invasive potential of the tumor is related to tumor cell associated proteolytic activity. This is leading to degradation of extracellular matrix and basement membranes. [6] Plasmin cleaves the extracellular components as fibronectin, laminin and collagen. The binding of uPA to uPA receptor (uPAR) initiates the enzymatic activity of plasmin. Plasmin activator inhibitor (PAi) binding the active site of uPA, prevents the formation of the uPA/uPAR complex and the enzymatic activity of plasmin. So PAi is a factor regulating the invasiveness of prostate cancer.[26] Plasminogen activator inhibitor type 1 (PAI-1) is undetectable in cells of some aggressive malignancies, but present in the stroma of tumor-associated microvasculature. Expression of PAI-1 by malignant prostate cells resulted in a less aggressive phenotype, presumably by inhibition of uPA activity, suggesting pharmacologic or molecular inhibition of uPA activity as a potential therapeutic target. [27]uPA-specific inhibitors can decrease primary tumor volume and invasiveness as well as metastasis in a model of prostate cancer where uPA has been implicated as a major pathogenesis factor.[23]. Plasminogeen comes to expression in liver and bone marrow.[10,18]

KCNE2
In the American manuscript [22] there was a down regulation expected of KCNE2 in the canine prostate carcinoma. KCNE2 was identified as the 7050 Da peak.[22] In addition there is a down regulation of KCNE2 in human gastric cancer. KCNE2 possibly could delay the proliferation and tumor genesis of the stomach. The protein is over expressed in the purkinje fibers of the heart.[21] The function of KCNE2 is to control the repolarisation of the ventricle. It has got a critical role in the regulation of voltage gated potassium channels.[14,34]
MYH16





RNA isolation and cDNA synthesis
RNA has been isolated using a RNaesykit (Qaigen), according to the manufacturers protocol. CDNA was synthesized from 500 ng RNA. With RNA isolation, the amount RNA isolated was measured by photospectometry (Nanodrop ND 1000).                                                                                                     ACE:    500/366 ng/µl =	1.37µl                                                                                            CAPE:  500/690.8 ng/µl = 	0.72µl                                                                                      CPA:     500/318.8 ng/µl =	1.57µl                                                                                        K9TCC:  500/1087 ng/µl =	0.4                                                                                               CDNA was synthesized using  the iScript cDNA synthesis kit (Bio-Rad laboratories, Hercules, CA) according to the manufacturing protocol.                                                                                                                                    This kit contained:                                                                                                                        -5x iScript Reaction mix 100 µl                                                                                                            -Nuclease free water                                                                                                                     -iScript reverse transcriptase                                                                                                                   The reaction set up was:                                                                                                                        -5x iScript Reaction mix         4 µl                                                                                                                                          -iScript reverse transcriptase   1 µl                                                                                               -Nuclease free water                x µl                                                                                                                   -RNA template                         x µl                                                                                                  -total volume:                         20 µl                                                                                                We used reverse transcriptase negative controls (RT-) to verify that there wasn’t formed a template string. In that reaction set up, there wasn’t used any reverse transcriptase and 1µl more nuclease free water.                                                                                                                                         The complete reaction mix was incubated by:                                                                              -5minutes at 25ºC                                                                                                                            -30 minutes at 42 ºC                                                                                                                            -5 minutes at 85 ºC                                                                                                                        -hold at 4 ºC                                                                                                                                  
 QPCR                                                                                                                                                     The qPCR was performed using a Bio-Rad MyiQ detection system with SYBR green fluorophore.  Dog specific primers for APO-CI, HMG-17, KCNE2, MYH16 had already been developed (table 2-6). The sequences of APO-CI are: 
Upper sequence 5’  3’ 24-mer GCT-CCC-GGT-TTT-GGT-GGT-GGT-TCT
Lower sequence 5’  3’ 21-mer GCT-GCC-CGG-GCC-TTG-TCT-TCC
The sequences of HMG-17 are: 
Upper sequence 5’  3’ 24-mer ATG-CAG-AAT-TTT-GTT-TTA-CTT-TTT
Lower sequence 5’  3’ 20-mer GGT-GTT-TTT-CCT-TCG-TTA-TCA-AT
The sequences of KCNE2 are: 
Upper sequence 5’  3’ 19-mer GAC-AAT-TGG-CGC-AGG-AAC-A
Lower sequence 5’  3’ 21-mer GGT-GGT-AGG-GGT-CAT-TGG-AGT
The sequences of MYH16 are:
Upper sequence 5’  3’ 24-mer GTG-TCG-CCT-CCG-GGG-TTT-CCT-TAT
Lower sequence 5’  3’ 24-mer GAG-CGG-CTT-GAC-CTT-GTT-GTA-GAG
The primers of plasminogen still had to be developed (view tabel5). Finally Primer pair 3 of plasminogen (XM_533468) was developed  by NCBI/Nucleotide, Oligo Explorer, BLAT, MFOLD and BLAST. The completed PCR product was evaluated using a 1% agarose gel (0,6 g agarose in 60 ml TBE (Tri-borate-EDTA)) electrophoresis with ethidium bromide staining. 5 µl of loading buffer with 25 µl of PCR product was mixed. The gel was visualised under UV light. The size of the amplification product was estimated by comparison to a 100-basepair molecular size standard ladder.                                                                                                    A Big Dye Terminator Cycle Sequencing of plasminogen was performed. The following materials were added before the cycle sequence was initiated:                                                                                            -1 µl Terminator Ready reaction Mix BDT                                                                                  -3 µl of PCR product from the qPCR plate, 10 x diluted                                                                           -1 µl upper primer or lower primer 30x diluted                                                                                                       -2 µl buffer                                                                                                                                              -3 µl MQ                                                                                                                                                         - total volume 10 µl                                                                                                                     Next everything was vortexed and the cycle sequence is initiated. There were 25 cycles in which:                                                                                                                                             - an accelerated heating occurred to 96°C                                                                                       - 30 sec. 96°C                                                                                                                                - 15 sec. 50°C                                                                                                                                 - accelerated heating to 60°C                                                                                                         - 60°C  2 min                                                                                                                               After 25 cycles a constant temperature was maintained until the device was stopped.   Sephadex purification: a 96 wells plate of sephadex was placed in the Multiscreen MAHV  filtration plate. Before the test, 300 µl mQ was inserted in every well and the plate was incubated at room temperature. The plate had already been placed in the cold storage and centrifuged. Furthermore 20 µl of mQ was added to the samples with the reverse and forward primers and then 30 µl was added to two wells. The mini columns that have not been used were covered with tin foil. The MAHV plate had been placed on top of a sequencing plate and the whole entity was centrifuged for 5 minutes. These sequences were measured. Next, the sequencing machine had been set up and the electrophoresis was performed. Finally plasminogen appeared to be expressed in this Big Dye Cycle Sequencer. In Blast we identified the protein to be plasminogen.
The sequences of primer 3 plasminogen are:
Upper sequence 5’  3’ 24-mer GTATCGCTATGAGTATCTGAATGG    
Lower sequence 5’  3’ 21-mer AGTGACTCCTTGTAAAATGTA  










Table 1: cell lines and tissues. T= best annealing temperature primers. The positive controle tissues of the primers are mentioned in red.
ACE	canine prostate cancer cells (Ace-1).[9]
CAPE	non-neoplastic epithelium cell line from the canine prostate. (CAPE)[8]
CPA	spontaneous carcinoma cell line from the canine prostate[8].
C9TCC	Canine transitional cell carcinoma cell line [11]
CMT1	Canine mammary tumor 1
CMT3	Canine mammary tumor 2
CMT5	Canine mammary tumor 5
CMT8	Canine mammary tumor 8
CMT9	Canine mammary tumor 9
P114	mammary carcinoma cell line [10]
fibro	Fibroblastic tissue	Positive control  Primer:	T






Table 2 primer properties APO-C-I
Upper sequence 5’  3’ 24-mer GCT-CCC-GGT-TTT-GGT-GGT-GGT-TCTLower sequence 5’  3’ 21-mer GCT-GCC-CGG-GCC-TTG-TCT-TCC 
DNA 250 Pm, Salt 50mM	Upper Primer	Lower Primer
Primer TmPrimer Location	64.8 ºC193 .. 216	65.5  ºC339 .. 319
Product Tm – Primer TmPrimers Tm DifferenceOptimal Annealing Temperature	 15.1 ºC   0.7 ºC 60.4 ºC
Product LengthProduct Tm (%GC method)Product GC Content	 147 BP 79.9 ºC 59.9 %
 
Tabel 3 primer properties Hmg-17
Upper sequence 5’  3’ 24-mer ATG-CAG-AAT-TTT-GTT-TTA-CTT-TTTLower sequence 5’  3’ 20-mer GGT-GTT-TTT-CCT-TCG-TTA-TCA-AT 
DNA 250 Pm, Salt 50mM	Upper Primer	Lower Primer
Primer TmPrimer Location	47.4 ºC375 .. 398	45.7 ºC574 .. 555
Product Tm – Primer TmPrimers Tm DifferenceOptimal Annealing Temperature	 23.5 ºC   1.6 ºC 47.3 ºC
Product LengthProduct Tm (%GC method)Product GC Content	   200 BP   69.2 ºC   31.0%
 
Tabel 4 primer properties KCNE2
Upper sequence 5’  3’ 19-mer GAC-AAT-TGG-CGC-AGG-AAC-ALower sequence 5’  3’ 21-mer GGT-GGT-AGG-GGT-CAT-TGG-AGT 
DNA 250 Pm, Salt 50mM	Upper Primer	Lower Primer
Primer TmPrimer Location	54.2 ºC70 .. 88	54.1 ºC256 .. 236
Product Tm – Primer TmPrimers Tm DifferenceOptimal Annealing Temperature	22.6 ºC  0.2 ºC55.0 ºC
Product LengthProduct Tm (%GC method)Product GC Content	   187 BP    76.7 ºC   49.7 %
 
Tabel 5: primer properties MYH-16Upper sequence 5’  3’ 24-mer GTG-TCG-CCT-CCG-GGG-TTT-CCT-TATLower sequence 5’  3’ 24-mer GAG-CGG-CTT-GAC-CTT-GTT-GTA-GAG 
DNA 250 Pm, Salt 50mM	Upper Primer	Lower Primer
Primer TmPrimer Location	 63.9 ºC2349 .. 2372	58.2 ºC2499 .. 2476
Product Tm – Primer TmPrimers Tm DifferenceOptimal Annealing Temperature	 19.2 ºC   5.6 ºC 56.8 ºC
Product LengthProduct Tm (%GC method)Product GC Content	     151 BP     77.4 ºC    53.6 %

Tabel 6 primer properties Plasminogen primer 3
Upper sequence 5’  3’ 24-mer GTATCGCTATGAGTATCTGAATGG    Lower sequence 5’  3’ 21-mer AGTGACTCCTTGTAAAATGTA  
DNA 250 Pm, Salt 50mM	Upper Primer	Lower Primer
Primer TmPrimer Location	49.6 ºC9 .. 32	40,8 ºC775 .. 755
Product Tm – Primer TmPrimers Tm DifferenceOptimal Annealing Temperature	 36,4 ºC8,8 ºC51,4 ºC






The results of the qPCR of the reference genes HPRT and RPL8 are showed in table 1 and two and figure 3 and 4. In the tables and figures are S1- S7 the standard curve, ACE and CPA the prostate carcinoma cell lines, CAPE is the cell line of the normal prostate and K9TCC is the transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of the masticatory muscles (chewing muscles of the jaw). RT- are the negative controls of the cell lines (which are reverse transcriptase negative). MQ are the negative template controls. The positive controls are PCAi, liver, heart and masseter tissue. N/A means not available. This means that the Ct values couldn’t be measured during the cycles which where performed in the qPCR. The higher the expression, the lower the Ct values. The mean expression of the cell lines and PCAi in Ct values are 15 in RPL8 with a efficiency of 102,3%. In HPRT the mean expression was 20 with a efficiency off 104%. The Ct values of the possible marker proteins are going to be compared to these CT values.
Apo-cI (apolipoprotein cI) is expressed in the cell lines, but not all of the NTC’s are N/A. The prostate tumor cell lines (ACE and PCA) did come slightly more to expression then the non tumor cell lines (CAPE and K9TCC)  which had mean Ct values of 28,44 and 28,89 respectively. PCAi is clearly over expressed compared to other tissues. The efficiency was 89,1%. From this it can be concluded that APO-Ci comes to an over expression in the prostate tumor cell lines in comparison to the non-tumor prostate cell lines. A bigger difference can be seen in expression between tissues of PCAi and other tissues. The prostate carcinoma tissue PCAi, had Ct-values are between 20 and 21, only the expression of liver tissue was higher with a mean Ct value of 15,4. Other tissues showed  lower expression of APO-Ci. As a positive control liver tissue was used because  literature showed that that APO-Ci is highly expressed there. As a negative control, reverse trancriptase cell lines (RT-) have been used in the qPCR. Not all of the Ct values of the RT- were N/A. The RT-  Ct values where 2,85 above the mean. So the cell lines had a higher expression then the RT- cell lines (see table 3 and figure7).                                                   
HMG 17 (nonhistone chromosomal protein hmg-17) is highly expressed as well in the prostate as all other tissues  except the masseter and liver tissues. The NTC’s are almost all N/A or higher then 34,35. In the prostate carcinoma cell lines PCA and ACE, HMG-17 is also highly expressed. ACE has a mean Ct value of 19,65 and  CPA  a value of 21,52.  In addition, the RT- of ACE is N/A, so ACE has a highly expressed of HMG-17. In the cell lines there is hardly any difference in expression, comparing  the prostate adenocarcinoma ACE and CPA to CAPE and K9TCC. HMG-17 is also highly expressed in PCAi with a mean Ct value of 20,89. Also the heart and the fibroblast tissue have got a high expression of HMG-17 with mean Ct values of  21,4 and 21 respectively. Only in the masseter and liver tissue, there is a low expression of HMG-17 (see table 2 and figure8).
KCNE2 shows two peaks in the CT curve. The standard curve has only one peak. Also the lower concentration have two peaks, so at the lower concentrations, not only the primers are multiplied. There are two peaks at TM84º and TM 80 ºC.  The efficiency is 133% and was  obtained  by deleting several values out of the standard curve. In addition, the NTC’s aren’t all N/A and there are hardly any differences seen in expression between cell lines and tissues (see table2 and figure 9) .
Myh16 is over expressed in prostate carcinoma cell lines, because the NTC’s are N/A and the positive control, in this case the masseter muscle, has a Ct value of 29,5, which is low compared to the standard curve. MYH16  isn’t higher expressed in prostate carcinoma cell lines (CPA and ACE)  then in the non prostate tumor cell lines (K9TCC and CAPE). The RT- values are all N/A. The efficiency of  the standard curve is 165% (see figure 10 and table 3)














Tabel 2: Rough data qPCR Ct values may-oktober 2008 of the reference gene HPRT and the possible marker proteins  Apo CI, HMG17 and KCNE2. S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in red are PCAi, liver, heart and masseter. N/A means not available




































































Tabel 3: Rough data qPCR Ct values may-oktober 2008 of the reference gene RPL8 and the possible marker proteins  MYH16 and plasminogen primer 3. S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in red are PCAi, liver, heart and masseter. N/A means not available.
















































































































Figure 4: qPCR expression in Ct values of the reference gene RPL8. S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in are PCAi, liver, heart and masseter. N/A means not available. The higher the expression,the lower the Ct values. De expression of the cell lines and PCAi are in RPL8  15 with a mean efficiency of 102,3%

Figure 5: qPCR  expression in Ct values of the reference gene HPRT S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in are PCAi, liver, heart and masseter. N/A means not available. The higher the expression,the lower the Ct values. De expression of the cell lines and PCAi are in HPRT 20 with a mean efficiency of 104%.

Figure 6: qPCR  expression in Ct values of the possible prostate carcinoma marker plasminogen.S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in are PCAi, liver, heart and masseter. N/A means not available. The higher the expression,the lower the Ct values. The expression of the plasmin precursor plasminogen was low in the tumor cell lines. One of the Ct values is N/A. The  RT- values are N/A in general, only the RT- value  of CPA was 38,0. The expression of the normal liver had a high expression with a Ct value of 17,8. The efficiency was 108%.





Figure 8: qPCR  expression in Ct values of the possible prostate carcinoma marker HMG-17. S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in are PCAi, liver, heart and masseter. N/A means not available. The higher the expression,t he lower the Ct values. HMG 17 (nonhistone chromosomal protein hmg-17) is highly expressed in the prostate and al other tissues except the liver and masseter tissue. There is hardly any difference in expression between the prostate tumor cell lines and CAPE and K9TCC. The NTC’s are N/A or higher then 34,35

Figure 9: qPCR expression in Ct values of the possible prostate carcinoma marker KCNE2. S1-S7 is the standard curve, ACE and CPA are prostate carcinoma cell lines, CAPE is the cell line of the normal prostate, K9TCC is the canine transitional carcinoma cell line. PCAi is a prostate carcinoma tissue. CMT1-CMT9 and p114 are the mammary tumors, fibro is fibroblastic tissue, masseter is one of masticatory muscles (chewing muscles). RT- are the negative controls of the cell lines. MQ are the negative template controls. The positive controls, in are PCAi, liver, heart and masseter. N/A means not available. The higher the expression,t he lower the Ct values. The efficiency of 133% was obtained after deleting a lot of points out of the standard curve. In addition, not all of the NTC’s are N/A and there are hardly any differences in expression between cell lines and tissues 











The aim of this research is to investigate if one or more of the identified protein peaks are in over expression in the prostate carcinoma cell lines (CPA and ACE)  compared to the transitional cell line (K9TCC) and the cell line of the normal prostate (CAPE). The proteins can be measured in the blood of  dogs suffering from prostate carcinomas. The proteins have been identified based on molecular weight, using the SELDI-TOF mass spectrometer.[21]           It’s possible that if there wasn’t found any over expression of  these proteins in canine prostate carcinomas, there still could be found a protein peak in the blood. It could be possible that the identification of the protein peaks wasn’t correct. It can be that, because of this, there has been  research about the expression of the wrong proteins. An other possibility is that the tissue of the prostate is damaged by the invasiveness of the tumor and that the protein leak into the blood vessels.                                                                                                                           A problem is that the protein peak of 2085 Da wasn’t identified. It could be that this protein has got the highest expression in the prostate carcinoma cell lines compared to the other cell lines and that this protein is the best marker.                                                                                  The proteins KCNE2 and plasminogen are expected to be down regulated  in prostate tumors according the manuscript of researchers from the united states. [22,29] It is possible that therefore these proteins won’t be expressed in prostate tumor cell lines or tissues.                      So the major concern is that the proteins are found in the blood of dogs with canine prostate carcinomas and  that there is an expression of these proteins in the prostate.  But there is rather a higher expression measured  in the prostate carcinoma cell lines then in the K9TCC and CAPE cell lines. This way prostate carcinomas can be distinguished from  other ways by which prostate carcinomas can leak into the blood  like prostatitis. This is one of the disadvantages of PSA, the current human marker protein for prostate carcinomas. PSA  is over expressed in prostate carcinomas as well as in prostatitis, or other causes of leakage of PSA into the circulation system.  This causes the patient to undergo painful biopsies, to find out if there really is a prostate carcinoma, while often  it appears to be a false positive test afterwards. So the marker protein shouldn’t be enhanced in the blood, when there isn’t a prostate carcinoma. The identified protein peaks where absent in non-cancer diagnoses, non urogenital cancer, bladder cancer and healthy control animals, but it was unclear  if these peaks were absent in other prostate diseases like prostatitis.[22] That’s why it’s important to investigate if the expression of the proteins is enhanced in prostate carcinomas compared to healthy prostate tissue or  transitional cell carcinomas.
Apo-cI (apolipoprotein cI) is expressed in the cell lines, but not all of the NTC’s are N/A. The prostate tumor cell lines (ACE and PCA) did come slightly more to expression then the non tumor cell lines(CAPE and K9TCC)  which had mean Ct values of 28,44 and 28,89 respectively. The efficiency was 89,1%, which is low (target number between 95 and 105%). From this it can not be concluded that APO-Ci comes to over expression in the prostate tumor cell lines in comparison to the non-tumor prostate cell lines. A bigger difference can be seen in expression between tissues of PCAi and other tissues. The prostate carcinoma tissue PCAi, had Ct-values between 20 and 21, only the expression of liver tissue was higher with a mean Ct value of 15,4. Other tissues showed  a lower expression of APO-Ci. As a positive control liver tissue was used,  because  literature showed that that APO-Ci is highly expressed there. As a negative control, reverse trancriptase cell lines (RT-) have been used in the qPCR.  Not all of the Ct values of the RT- were N/A. The RT-  Ct values where 2,85 above the mean value. So the cell lines had a higher expression then the RT- cell lines (see table 3 and figure7).  APO-Ci was one of the proteins which was identified as one of  the possible marker protein. So it can be detected in the plasma  of dogs with prostate carcinomas.           An other research to possible biomarkers for canine prostate carcinoma  is performed in Hannover at the moment. If the marker protein which is detected there,  has a worse expression in prostate carcinoma cell lines compared to K9TCC or CAPE cell lines, or if it isn’t detectable in the blood, then APO-Ci could be a possible marker protein, according to the high expression  of prostate carcinoma  tissues. It’s too bad  that the difference in expression between the prostate carcinoma cell lines and the other cell lines wasn’t bigger then this.  Other apolipoproteins have been revealed as potential marker proteins of human prostate carcinoma, which can exclude other prostate diseases from  prostate carcinomas.  These proteins are: apoliprotein A II (APO-A-II) and apolipoprotein D(APO-D). [12,15]  So it could be that APO-CI is a potential marker protein, although the odds are very small. 
HMG 17 (nonhistone chromosomal protein hmg-17) is highly expressed as well in the prostate as all other tissues  except the masseter and liver tissues. The NTC’s are almost all N/A or higher then 34,35. In the prostate carcinoma cell lines PCA and ACE, HMG-17 is also highly expressed. ACE has a mean Ct value of 19,65 and  CPA  a value of 21,52.  In addition, the RT- of ACE is N/A, so ACE has a highly expressed of HMG-17. In the cell lines there is hardly any difference in expression, comparing  the prostate adenocarcinoma ACE and CPA to CAPE and K9TCC. HMG-17 is also highly expressed in PCAi with a mean Ct value of 20,89. Also the heart and the fibroblast tissue have got a high expression of HMG-17 with mean Ct values of  21,4 and 21 respectively. Only in the masseter and liver tissue, there is a lower expression of HMG-17 (see table 2 and figure8). So HMG-17 isn’t quite specific for the detection of  prostate carcinomas. HMG-17 had a very nice standard curve with an efficiency of 99%.                                                                                                                                        HMG-17 isn’t very likely to become a marker protein for canine prostate carcinomas as a result of the low specificity between the expression of the different cell lines It was expected that HMG-17 would be a promising marker protein, because it would have a big part in organogenesis and it’s presence could indicate enhanced cell division. In addition it has  a part in the Wnt β-catenine pathway. In a research  study it appeared that with the transition to a hormone insensitive prostate tumor, the expression of the androgen receptors increased. The interaction between  the androgen receptors and the Wnt-signal, gives an advantage to the growth of prostate tumor cells. Physiological levels of androgen decreased the growth and the transformation of tumor cells, which are mediated by the Wnt-signal and the androgen receptor over expression. Androgen receptor over expression enhances the Wnt/β-catenine transcription activities.   β-catenine contributes to the development of prostate cancer by enhancing the androgen receptor transcription activity, due to the presence of androgens. On castration level the androgen receptor interacts with the Wnt-signal and increases the formation of prostate cancer cell proliferation. The over expression of the androgen receptor increases the malignity and the transformation of prostate cancer cells. The reduction to physiological levels of androgens can reduce the malignity and refractory prostate cells. This is possibly caused by the inhibitation of the androgen receptor in the Wnt/β-catenine signal path.[31]                                                                                                                                             In addition HMG-17  has an interaction with PITX2. When the Wnt-signal path is activated, the β-catenine is not degraded and can go through the nuclear  membrane.                                                                                                                    The β-catenine will then interact with the HMG17-PITX2 complex, by which this complex is activated and  transcription can take place. Without the Wnt-signal the β-catenine will be degraded and the PITX2 HMG-17 complex won’t be activated. In absence of the β-catenine the HMG17 protein binds the home domain factor PITX2 and inhibits its function. [5]         From research it appeared that activation of the Wnt-pathway signal in the prostate epithelium, leads to hyperplasia and transdifferentiation in squamos metaplasias. The transdifferentiation of prostate epithelium to squamos metaplasias is an early effect and after that the PIN-like lesions will occur. So the higher expression of the androgen receptors in the hormone insensitive stage, will interact with the Wnt-signal and stimulates the Wnt-pathway. With the presence of the Wnt-signal, β-catenine will go through the cell and interacts with the HMG17-PITTX2 complex and  as a result this complex stimulates the transcription and this way also the cell division activity. Furthermore β-catenine stimulates the heightened transcription activity of the androgen receptor and the tumor growth. This is why it’s against the odds that HMG17 doesn’t have an enhanced expression in the prostate tumor cell lines in comparison to the standard prostate cell line and the transitional cell carcinoma cell line. In that case HMG17 would be a potential marker, in which we could explain the over expression.
KCNE2 shows two peaks in the CT curve. The standard curve has only one peak. Also the lower concentrations have two peaks. So,  at the lower concentrations,  not only the primers are multiplied. There are two peaks at TM 84º and TM 80 ºC.  This points at a primer dimer problem or a second product. If there was a water contamination, than the double peaks would appear at the same temperature. The efficiency is 133% and was  obtained  by deleting several values from the  standard curve. In addition, the NTC’s aren’t all N/A and there are hardly any differences seen in expression between cell lines and tissues (see table2 and figure 9) .  The probability that KCNE2 is an appropriate marker protein isn’t very high according to these double peaks, the small variation  in expression between the cell lines and the holes in the standard curve.
Myh16 is over expressed in prostate carcinoma cell lines, because the NTC’s are N/A and the positive control, in this case the masseter muscle, has a Ct value of 29,5, which is low compared to the standard curve. MYH16  isn’t higher expressed in prostate carcinoma cell lines (CPA and ACE)  then in the non prostate tumor cell lines (K9TCC and CAPE). The RT- values are all N/A. The efficiency of  the standard curve is 165% (see figure 10 and table 3). Because  the cell lines can’t be clearly distinguished, MYH16 isn’t the best candidate to choose as a marker protein. In addition, the standard curve with an efficiency of 165% doesn’t  make the protein expression very reliable.
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Figure 1: classification system of canine prostate tumors. In red the classification system of the world health organization[16]
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